Mirum Pharmaceuticals (NASDAQ:MIRM) Raised to “Strong-Buy” at Baird R W

Baird R W upgraded shares of Mirum Pharmaceuticals (NASDAQ:MIRM) to a strong-buy rating in a report released on Monday, Zacks.com reports.

MIRM has been the subject of several other reports. HC Wainwright raised their target price on shares of Mirum Pharmaceuticals from $58.00 to $66.00 and gave the company a buy rating in a research note on Monday. JMP Securities raised their target price on shares of Mirum Pharmaceuticals from $66.00 to $68.00 and gave the company a market outperform rating in a research note on Tuesday. SVB Leerink cut their target price on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an outperform rating for the company in a research note on Monday, March 18th. Morgan Stanley raised their target price on shares of Mirum Pharmaceuticals from $53.00 to $57.00 and gave the company an overweight rating in a research note on Tuesday. Finally, Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $34.00 to $39.00 and gave the company an outperform rating in a research note on Monday. Ten equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of Buy and an average price target of $53.64.

Mirum Pharmaceuticals Price Performance

MIRM stock opened at $29.25 on Monday. The stock has a 50-day moving average price of $25.39 and a two-hundred day moving average price of $27.24. The stock has a market cap of $1.38 billion, a PE ratio of -7.88 and a beta of 1.10. The company has a current ratio of 3.68, a quick ratio of 3.47 and a debt-to-equity ratio of 1.31. Mirum Pharmaceuticals has a 1 year low of $23.14 and a 1 year high of $35.56.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, May 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.14). Mirum Pharmaceuticals had a negative return on equity of 56.46% and a negative net margin of 69.67%. The firm had revenue of $69.22 million for the quarter, compared to the consensus estimate of $69.71 million. Equities analysts forecast that Mirum Pharmaceuticals will post -1.39 EPS for the current fiscal year.

Insider Transactions at Mirum Pharmaceuticals

In related news, COO Peter Radovich sold 4,303 shares of the business’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $25.80, for a total value of $111,017.40. Following the transaction, the chief operating officer now owns 29,013 shares in the company, valued at $748,535.40. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Mirum Pharmaceuticals news, Director Saira Ramasastry sold 5,000 shares of Mirum Pharmaceuticals stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $25.68, for a total value of $128,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Peter Radovich sold 4,303 shares of the business’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $25.80, for a total transaction of $111,017.40. Following the sale, the chief operating officer now directly owns 29,013 shares of the company’s stock, valued at $748,535.40. The disclosure for this sale can be found here. 22.87% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MIRM. Swiss National Bank increased its holdings in Mirum Pharmaceuticals by 1.3% during the 3rd quarter. Swiss National Bank now owns 54,400 shares of the company’s stock worth $1,719,000 after acquiring an additional 700 shares during the period. New York State Common Retirement Fund lifted its position in Mirum Pharmaceuticals by 0.4% during the 4th quarter. New York State Common Retirement Fund now owns 222,864 shares of the company’s stock valued at $6,579,000 after acquiring an additional 918 shares during the period. Janney Montgomery Scott LLC increased its stake in Mirum Pharmaceuticals by 5.3% during the 3rd quarter. Janney Montgomery Scott LLC now owns 18,925 shares of the company’s stock valued at $598,000 after purchasing an additional 950 shares in the last quarter. Golden State Equity Partners increased its stake in Mirum Pharmaceuticals by 5.3% during the 4th quarter. Golden State Equity Partners now owns 18,930 shares of the company’s stock valued at $559,000 after purchasing an additional 950 shares in the last quarter. Finally, Wetzel Investment Advisors Inc. grew its stake in shares of Mirum Pharmaceuticals by 71.4% in the first quarter. Wetzel Investment Advisors Inc. now owns 2,400 shares of the company’s stock worth $57,000 after acquiring an additional 1,000 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.